We are a clinical-stage regenerative medicine company. Our lead asset, MOTYS™, is an intra-articular biologic being developed to deliver localized potent anti-inflammatory and regenerative factors to patients suffering from osteoarthritis.
At Doron Therapeutics, we believe mobility is a gift. Our goal is to harness the natural healing power found in donated placental tissue — transforming a mother's generous gift into a breakthrough biologic therapy that helps people with knee osteoarthritis return to the active, pain-free lives they deserve.
Read our storyOsteoarthritis is a growing epidemic with limited therapeutic options available to patients and with no disease-modifying treatments. Prevalence is driven by an aging population, rising obesity rates, and increasing participation in high-impact sports. The need for effective, long-lasting therapies that can delay the progression of this chronic disease has never been greater.
MOTYS, our lead investigational product, is designed to take a fundamentally different approach to treating osteoarthritis and represents a paradigm shift in osteoarthritis treatment. Derived from placental tissue, MOTYS has been designed to consistently deliver powerful anti-inflammatory, tissue-protective, and anabolic factors directly inside the knee. The name MOTYS comes from the Latin word motus, meaning motion—reflecting our commitment to helping people regain the freedom of movement that osteoarthritis takes away.
Whether you're a physician, researcher, investor, or patient advocate, we'd love to hear from you.